XNAS
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | Q1 2026 | -0.33 | -0.38 | -15.15% | $3.2M | ❌ Miss | -0.05% | +1.86% | — |
| 2024-11-14 | Q1 2025 | -0.11 | -0.04 | +63.64% | $9.0M | ✅ Beat | +18.69% | +95.14% | -23.55% |
| 2024-10-08 |
| Q4 2024 |
| -0.10 |
| -1.14 |
| -1040.00% |
| $5.9M |
| ❌ Miss |
| -13.84% |
| -22.91% |
| -37.71% |
| 2024-05-13 | Q3 2024 | -0.12 | -0.14 | -16.67% | $7.5M | ❌ Miss | +5.09% | -62.26% | -63.15% |
| 2024-02-13 | Q2 2024 | -0.18 | -0.19 | -5.56% | $7.0M | ❌ Miss | — | — | — |
| 2023-11-13 | Q1 2024 | -0.18 | -0.27 | -50.00% | $7.0M | ❌ Miss | +6.44% | +1.37% | +5.59% |
| 2023-09-06 | Q4 2023 | -0.17 | -0.21 | -2352.94% | $8.3M | ❌ Miss | -10.34% | -16.22% | -23.10% |
| 2023-05-08 | Q3 2023 | -0.19 | -0.20 | -5.26% | $7.4M | ❌ Miss | -6.87% | +0.69% | +18.90% |
Showing last 8 quarters.